1. Scrip
  2. >>Business

Lilly Sales Swing Back As Pandemic, Loss Of Exclusivity Pressures Recede

Diabetes, Immunology, Oncology Lead 28% Sales Jump

 
• By Alaric DeArment

The drug maker is looking ahead to potentially big approvals of donanemab for Alzheimer’s disease and Mounjaro for obesity by the end of the year.

• Source: Shutterstock

Eli Lilly and Company rocketed back to growth in the second quarter of 2023 after multiple quarters in which revenues declined, as the company’s type 2 diabetes, oncology and immunology franchises carried sales back into the black and pressure from loss of exclusivity and COVID-19 lightened. Meanwhile, the drug maker is gearing up for potential approvals and launches of drugs for Alzheimer’s disease and obesity while progressing on the launch of its BTK inhibitor in non-Hodgkin’s lymphoma that won approval earlier this year.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

Roivant Tightens Leadership Grip On Immunovant, Narrows Near-Term IMVT-1402 Focus

 
• By Mandy Jackson

Roivant president Eric Venker was named CEO of Immunovant to guarantee execution of the development plan for IMVT-1402 in six indications, now including Sjögren’s disease and cutaneous lupus erythematosus.

Alis Biosciences Launches To Free Cash From Stalled-Out Biotechs

 
• By Mandy Jackson

As investors have begun to ask troubled drug developers to suspend operations and return remaining cash to shareholders, Alis has stepped forward with a new fund aiming to facilitate that.

Top-Selling Drugs 2024: Keytruda, Ozempic And Dupixent Dominate

 
• By Eleanor Malone

Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.